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Abstract
Background Breathlessness, cough and fatigue are distressing
symptoms for patients with lung cancer. There is evidence that
these three symptoms form a discreet symptom cluster. This
study aimed to feasibly test a new non-pharmacological inter-
vention for the management of the Respiratory Distress
Symptom Cluster (breathlessness-cough-fatigue) in lung
cancer.
Method This was a multi-centre, randomised controlled non-
blinded parallel group feasibility trial. Eligible patients (pa-
tients with primary lung cancer and ‘bothered’ by at least
two of the three cluster symptoms) received usual care plus
a multicomponent intervention delivered over two interven-
tion training sessions and a follow-up telephone call or usual
care only. Follow-upwas for 12 weeks, and end-points includ-
ed six numerical rating scales for breathlessness severity,
Dyspnoea-12, Manchester Cough in Lung Cancer scale,
FACIT-Fatigue scale, Hospital Anxiety and Depression scale,
Lung Cancer Symptom Scale and the EQ-5D-3L, collected at
baseline, week 4 and week 12.
Results One hundred seven patients were randomised over
8 months; however, six were removed from further analysis
due to protocol violations (intervention group n=50 and con-
trol group n=51). Of the ineligible patients (n=608), 29 %
reported either not experiencing two or more symptoms or
not being ‘bothered’ by at least two symptoms. There was
29 % drop-out by week 4, and by week 12, a further two
patients in the control group were lost to follow-up. A sample
size calculation indicated that 122 patients per arm would be
needed to detect a clinically important difference in the main
outcome for breathlessness, cough and fatigue.
Conclusions The study has provided evidence of the feasibil-
ity and acceptability of a new intervention in the lung cancer
population and warrants a fully powered trial before we reach
any conclusions. The follow-on trial will test the hypothesis
that the intervention improves symptom cluster of breathless-
ness, cough and fatigue better than usual care alone. Full eco-
nomic evaluation will be conducted in the main trial.
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Introduction
Breathlessness, cough and fatigue are distressing symptoms
for patients with lung cancer [1,2]. Breathlessness occurs in up
to 90% of patients and is distressing for both patients and their
carers, with a deleterious effect on health related quality of life
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[3]. Cough occurs in 47–86 % of patients, and for some, it can
be more distressing than breathlessness [4]. Patients report
fatigue (prevalence 50–90 %) as one of the most important
and distressing symptoms related to cancer and its treatment
[5]. Patients often experience multiple symptoms.
Longitudinal data suggests that breathlessness, cough and fa-
tigue form a discrete cluster, named the Respiratory Distress
Symptom Cluster [1]; patients with one symptom will often
suffer from one or both of the others [6]. This has implications
for management, as potentially, the symptoms in the cluster
need to be managed concurrently if we are to observe signif-
icant improvements in individual symptoms that are part of
the cluster.
Despite the complexity of symptomatology in people with
lung cancer, non-pharmacological symptom management in-
tervention research has focused on breathlessness, cough and
fatigue as single symptoms [7]. Breathlessness self-
management techniques are clinically cost-effective [8–10].
Interventions such as exercise and acupressure are effective
in the management of cancer-related fatigue [11–13], but these
have not been robustly tested in intrathoracic malignancies.
Cough has not received the same attention as other cancer
symptoms, although there is a developing evidence-base
to support non-drug measures for cough [14,15].
However, since these symptoms often occur together, it
is important to rigorously test interventions that target
multiple symptoms. To address this gap, we applied the
Medical Research Council (MRC) framework for the de-
velopment and evaluation of complex interventions [16]
to develop an intervention for the (self) management of
the respiratory distress symptom cluster (breathlessness-
cough-fatigue). The work conducted during the interven-
tion theory and modelling development stages has been
previously reported [17–19] and centres around the views
of patients, their caregivers and health professionals on
the components of a non-pharmacological intervention
for the management of the symptom cluster as well as
preferences of delivery of the intervention.
This paper reports the findings of a feasibility randomised
trial of a new intervention, the Respiratory Distress Symptom
Intervention (RDSI). The main objectives were to
1. Assess the feasibility and acceptability of the intervention
to patients
2. Test the design and practicality of the protocol with regard
to recruitment, patient withdrawal and completion of
assessments
3. Examine the performance of the different symptom out-
come measures in order to inform a power calculation for
the follow-on trial
4. Provide proof of principle for any positive contribution of
the intervention to the management of the symptom
cluster
Methods
Study design
This study was a non-blinded randomised feasibility trial com-
prising two groups: (i) intervention group receiving usual care
and RDSI and (ii) control group receiving usual care only.
Both groups also received the Macmillan breathlessness and
fatigue information booklets.
Participants and settings
This multisite study had 11 participating centres, including
seven secondary care teaching hospitals, two specialist cancer
centres and two district general hospitals, located in the north
of England. Patients from each of the participating sites at-
tending lung cancer out-patient clinics were screened for eli-
gibility by the research nurse in collaboration with the attend-
ing clinician. Eligible participants were adults with primary
lung cancer, an expected prognosis of at least 3 months, a
World Health Organisation (WHO) Performance Status 0–2,
and reported being ‘bothered’ from at least two of the cluster
symptoms: breathlessness or cough or fatigue, in any combi-
nation. Patients were screened for symptom eligibility by ask-
ing (i) Do you have breathlessness/cough/fatigue, and if ‘yes’,
(ii) Are you bothered by breathlessness/cough/fatigue?
Patients were excluded if they had an acute exacerbation of
chronic obstructive pulmonary disease (COPD) or chest infec-
tion within the past 4 weeks that necessitated a change in
medication, received radiotherapy to the chest or chemother-
apy in the previous 4 weeks, or had surgical treatment for lung
cancer in the previous 6 weeks.
The intervention
RDSI includes core components that were most highly rated
by patients, carers and clinicians in our previous work [17–19]
and with the strongest evidence-base:
1. Controlled breathing techniques: consisting of diaphrag-
matic breathing exercises and calming techniques prac-
ticed twice a day and used as needed for episodes of
intense breathlessness and/or anxiety [8–10].
2. Cough easing techniques: includes education (capacity
for voluntary cough easing), identifying warning signs
for cough and using modified swallow technique/
relaxed throat breathing [14,15].
3. Acupressure: a small number of acupressure points are
taught: L7, L9, LI4 (located on the hand and wrist areas),
CV21 and 22 (sternum), and ST36 (knee). Patients apply
pressure for 1 min at least twice a day [11–13]. The selec-
tion of points and the approach to acupressure selected
was based on reviewing the literature and obtaining
3374 Support Care Cancer (2015) 23:3373–3384
consensus with acupuncture-trained therapists. Points
were selected to affect all three symptoms of the cluster,
some based on our previous work too.
4. Information pack: supplementary written information giv-
ing practical advice about symptom experience and com-
munication strategies, sleep hygiene, activity management/
energy conservation strategies, anxiety management tech-
niques (such as the ‘calming hand’ technique) and carer
support, all collated from existing resources.
Training for all components included psycho-educational
counselling for internalising locus of control, acceptance that
learning the techniques is hard work and requires frequent
practice and setting realistic goals. Patients were taught the
core components individually during an initial face-to-face
session lasting up to 1 h and then repeated 1 week later to-
gether with discussion on the supplementary information. The
information pack was given to the patient on the first interven-
tion delivery session and discussed at the second visit. Patients
also received one follow-up telephone call 2 weeks after the
second face-to-face training session. The intervention was de-
livered in a community setting (in the patient’s home or in a
hospital/community facility near to a patient’s home). The
intervention was delivered by specialist nurses, physiothera-
pists and complementary therapists who received specific
training from the complementary therapy team at The
Christie Hospital NHS Trust, to deliver the intervention.
Training consisted of one face-to-face group session lasting
3 h and a follow-up refresher session half way through the
trial. To collect self-report details regarding use and percep-
tions of usefulness of the different intervention techniques,
patients in the treatment group were requested to complete a
daily diary for the first 4 weeks, then weekly until week 12. To
assess how ‘useful’ each core component was, participants
were asked to tick one of the following: scaled as ‘not at
all’, ‘a little bit’, ‘quite a bit’, and ‘very much’.
Outcome assessments
As this was a feasibility study, there were no designated pri-
mary or secondary outcome measures. Outcome assessments
for both patients and carers were collected at (i) baseline (be-
fore randomisation), (ii) week 4 (end of follow-up contact in
RDSI group) and (iii) week 12 (end of study). Participants
allocated to the intervention group were asked to complete a
daily diary for the first 4 weeks then weekly until week 12.
The diary was used to collect process data such as frequency
of use of the different core intervention components and their
perceived usefulness.
Breathlessness was assessed using six 0–10 numerical rat-
ing scales (NRS) including average and worst breathlessness
in the past 24 h, distress and unpleasantness associated with
breathlessness (higher scores worse), and relief from
breathlessness and ability to cope with breathlessness (higher
scores better) [10,20]. Breathlessness was assessed using the
Dyspnoea-12 (D-12) scale, a measure which consists of 12
items that measure a patient’s current level of breathlessness
severity incorporating physical and emotional domains
(scores range from 0 to 36, higher scores worse breathless-
ness) [21–23]. Its Cronbach alpha for the current study popu-
lation was excellent (α=0.9). Cough was assessed using the
Manchester Cough in Lung Cancer scale (MCLC), a 10-item
self-report questionnaire (scores range from 1 to 50, higher
scores worse) [24]. Fatigue was assessed using the 13-item
Functional Assessment of Cancer Therapy-Fatigue (FACIT-
F) (scores range from 0 to 52, higher scores worse) [25].
Non-single symptom questionnaires included the Lung
Cancer Symptom Scale, a nine-item visual analogue scale used
to assess lung cancer-related symptoms (scores range from 0 to
100 mm for each of the nine items, higher score denotes more
severe symptom experience) [26], the EQ-5D-3L (index and
visual analogue scale (VAS)) was used to describe and value
overall perceived health-related quality-of-life and the feasibil-
ity of collecting a preference-based measure of health status for
use in an economic evaluation within the follow-on trial [27],
the EQ-5D-3 was valued using UK population norms [28], and
the Hospital Anxiety and Depression scale (HADS) [29] was
used to measure anxiety and depression. The HADS consists of
a separate scale for anxiety and depression, each consisting of
seven items with scores ranging from 0 to 21 (higher scores
denote poorer outcome).
For each self-reported outcome measure, patients were re-
quested to rate on a NRS 0 to 10 scale its ‘ease of use’ (higher
score denotes greater ease of use) and ‘relevance’ to their
experience (higher score denotes greater relevance).
Sample and randomisation
As this was a feasibility study, no sample size calculation was
performed, and the convention of 30 patients per arm at the
end of the study (i.e. week 12) was used [30]. To achieve this,
the aim was to randomise 120 patients (60 patients per trial
arm) with an additional 60 carers, as available, to accommo-
date an anticipated high attrition of 50 % to last assessment.
The randomisation method consisted of minimisation (with a
random element) controlling for gender, age (69 or less; 70
and above) and lung cancer treatment group, and was con-
ducted by the Clinical Trial Unit at The Christie Hospital,
Manchester. The lung cancer treatment group included (i) no
further cancer therapy for patients who are being treated
symptomatically only, (ii) post-curative treatment for patients
who have completed potentially curative cancer therapy who
are on follow-up (i.e. no further cancer therapy is planned
unless they relapse) and (iii) on palliative cancer therapy
follow-up for patients who have incurable cancer.
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Ethical approval
Approval for the conduct of this study was provided by
the National Health Service (NHS) ethics and participat-
ing hospital governance committees (NHS reference: 12/
NW/0090). All participants provided informed signed
consent.
Statistical methods
The SPSS (v20) statistical computer package was used for
analysis. Generalised estimating equation (GEE) models
were applied to test the group effect, time effect and their
interaction. GEE automatically handle missing data via
correlation matrices and are generally robust to the choice
of correlation structure [31,32]. The estimated marginal
means and their pairwise comparison p values for all
scales by group and time point were calculated, and basic
t tests were also considered as a sensitivity analysis to
check the conclusions from these models.
Minimal clinically important differences (MCID) for
the key symptom outcome measures were calculated
using two main methods: anchor-based and distribution-
based methods [33–35] and were used to calculate the
sample size required for the follow-on trial. For
distribution-based calculations, the effect size (change af-
ter intervention divided by standard deviation of baseline
scores) was used to determine the lowest meaningful de-
tectable difference based on the underlying variability of
the reported data [35]. A medium effect size of 0.5 was
used. We applied this distribution-based method for each
main outcome for each symptom: Dyspnoea-12, MCLCS
and the FACIT-F. Anchor-based methods can use regres-
sion and a known MCID for a related variable or can use
a patient-rated impression of global change for use in a
receiver operator characteristic (ROC) cut-point analysis
to provide an anchor to define a small, medium or large
change [35]. Specifically, a reduction (week12 baseline)
in NRS worst breathlessness was used to define a wors-
ening (status = 0) and an increase as an improvement
(status = 1) for use in the ROC analysis. To calculate
the anchor-based MCID for Dyspnoea-12, we used the
previously reported NRS ‘breathlessness severity’ (i.e. re-
gression between D-12 and NRS, then using the MCID
for the NRS in the regression equation to gain the MCID
for D-12) and for the FACIT-F previously reported
MCID’s for different patient populations [36,37]. No ap-
propriate anchor was available for the MCLC. There are
recognised limitations for both methods of MCID calcu-
lation, and therefore, it is recommended that both MCID
methods are applied, where possible, to frame the
categorisation of effect size in the context of patient report
[35].
Results
Feasibility aspects
Participants
Figure 1 (CONSORT diagram) illustrates that 715 patients
were screened, and 107 eligible patients were randomised
between April 2013 and November 2013 to one of the
two trial treatment arms (intervention group (RDSI) n=
53 and control group n=54). Of the ineligible patients
(n=608), 29 % reported either not experiencing two or
more symptoms or not being bothered by at least two
symptoms. The average age of the patients was 67.7 years
(SD 9.6 years); 54 (53 %) were female and most (60 %)
reported all three symptoms at baseline. The two groups
were different in baseline COPD prevalence (control
group 50 % and RDSI group 28 %) and Lung Cancer
Symptom Scale (higher mean scores in the control group
(421) compared to the RDSI group (352) (Table 1).
Data completeness
Of the 107 randomised patients, four were found to not
meet the inclusion criteria (RDSI = 2 and control = 2)
and were removed from data analysis. A further two did
not provide any data at baseline; therefore, they were
removed from the analysis since they had not strictly
followed protocol. The total sample analysed was 101
patients (RDSI n=50 and control n=51).
By week 4 29/101 (29%), patients were withdrawn, and by
week 12, a further two patients in the control group were lost
to follow-up. No patients in the RDSI group were lost between
week 4 and week 12. Total attrition at 12 weeks was 30/101
(29.7 %). Since there was very little attrition after week 4, we
conducted sample size analyses based on observations at week
12.
At week 12, there were more drop-outs in the treatment
group (38 %) than the control group (24 %); however, this
was not statistically significant (χ2=2.5, df=1, p=0.1).
Logistic regression for drop-out status using age, gender, treat-
ment type and WHO score revealed no significant items.
Individually, only theWHO score was borderline significantly
associated with drop-out (χ2=4.0, df=1, p=0.044). GEE
models with an unstructured correlation parameterisation
were used, because of the differently spaced time intervals
for assessments.
Outcomes assessments
The six NRS breathlessness scales combined scored the
lowest for ease of use (6.5/10) and relevance (6.8/10), and
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the EQ-5D-3L was the best for ease of use (7.8/10) and
relevance (7.8/10) (Table 2).
Respiratory symptom cluster outcomes
Results for the respiratory symptom cluster outcomes (breath-
lessness, cough and fatigue measures) are presented as change
in mean scores from baseline to 4 and 12 weeks (Table 3).
Figure 2 demonstrates variability of the scores for each symp-
tom outcome measure at baseline, week 4 and week 12, al-
though with a trend in scores to show some improvement in
the RDSI group. Dyspnoea-12 was chosen as the primary
outcome for breathlessness for the follow-on trial because it
was significant in the GEE model at week 12 for the RDSI
group (see below), and patients rated it higher (scale of 0–10,
higher is better) than the set of NRS breathlessness scales for
ease of completion (6.7 versus 6.5) and relevance (7.1 versus
6.8) (Table 2).
Non-respiratory symptom cluster outcomes
The mean change from baseline to week 4 and baseline to
week 12 for the Lung Cancer Symptom Scale, HADS and
EQ-5D-3L is shown in Table 3, again with a positive pattern
in terms of improvement in the RDSI group.
The GEE models included the WHO score as a covariate
due to its potential relationship with drop-outs, although it was
usually non-significant. In a number of models (consistent
with Fig. 2), time was a significant term for some endpoints
(NRS ‘worst breathlessness’ and NRS ‘distress from breath-
lessness’, Dyspnoea-12 and MCLC), and group was signifi-
cant for others (Dyspnoea-12, EQ-5D-3L, Lung Cancer
Symptom Scale) due to imbalances at baseline. However,
when the differential effect of group was considered (i.e. the
group×time interaction term), only EQ-5D-3Lwas significant
(p=0.042 respectively) and was due to a change at week 12
(marginal mean difference at week 12 of −0.17 (SD 0.06,
95%CI [−0.04, −0.30]), p=0.009). The group differences at
Patients screened
n=715 
Ineligible: 608 
absence of 2 or more symptoms 
or not bothersome 176 
poor prognosis 40 
further treatment 55 
recent chemotherapy 130 
other reasons 128 
declined 74 
reason unknown 5 
Patients randomised n=107 
INTERVENTION ARM 
Allocated to RDSI n= 53 
Included in analysis n=50
Removed from further 
analysis: 
2 did not meet eligibility criteria; 
1 no baseline data 
CONTROL ARM
Allocated to control n=54 
Included in analysis n=51 
Removed from further 
analysis: 
2 did not meet eligibility 
criteria; 1 no baseline data
4 week assessment 
Patients n =31 
DO during intervention: 
4 too unwell; 1 died; 1 shingles; 
1 declined  
DO post intervention: 
1 died; 8 declined; 3 lost to 
follow-up 
4 week assessment 
Patients n = 41 
5 died; 4 declined; 1 lost 
to follow-up 
12 week assessment  
n =31 
12 week assessment
n =40 2 lost to follow-up 
Fig. 1 Study flow chart. RDSI Respiratory Distress Symptom Intervention, DO drop-out
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week 12 were also estimated, and only Dyspnoea-12 had a
significant result (marginal mean 5.19, SD 2.33, 95%CI [0.62,
9.75], Wald χ2=1.27, df=2, p=0.026), where the reduction
(improvement) was greatest in the RDSI group (Table 4).
Sample size calculations for follow-on trial
Attrition in the feasibility trial was 29.7 % and was highest in
the palliative care treatment group. The largest correlation of
Dyspnoea-12 to other breathlessness questionnaires used in the
feasibility study was the NRS worst breathlessness (r=0.416)
which has aMCID of 1 unit [20,33,35]. Using an anchor-based
regression analysis, a 1 U change in worst breathlessness was
equivalent to a 1.22 U change in Dyspnoea-12. Using the same
anchor, an ROC analysis estimated a cut-point (maximising
Youden’s J) and resulted in a Dyspnoea-12 MCID of 2.5 U.
A distribution-based analysis using a baseline effect size of 0.5
produced a Dyspnoea-12 MCID of 4.7. Based on these analy-
ses, we have taken a Dyspnoea-12 MCID conservative esti-
mate of 3 U to use in the sample size calculation. Since three
different variables are used as co-primary endpoints, to main-
tain an overall significance of 5 %, the separate parts of the
sample size are based on an alpha of 5 %/3. To detect a differ-
ence of 3 U in Dyspnoea-12, a sample size of 97 patients per
arm, with 80 % power, at 5 %/3 significance (for a one-sided t
test at week 12, adjusted for large correlation to baseline values
[37]). Allowing for 20 % attrition at week 12, then 122 patients
per arm should be recruited.
Using data from the sub-group of patients with ‘bothersome’
cough (66 % of the total sample), the MCLC had a mean
difference between the two treatment groups of 3.0 U. A
distribution-based analysis using an effect size of 0.5 produced
Table 1 Baseline sample
characteristics Variable Control (n=51) RDSI-LC (n=50)
Age (mean (SD)) 67.6 (9.1) 67.8 (10.1)
Gender frequency (%)
Male 25 (49.0) 22 (44.0)
Female 26 (51.0) 28 (56.0)
Symptom cluster frequency (%)
Breathlessness
Present 50 (98.0) 49 (98.0)
Bothersome (of those with breathlessness ‘present’) 50 (100.0) 48 (98.0)
Cough
Present 41 (80.4) 40 (80.0)
Bothersome (of those with cough ‘present’) 32 (78.0) 35 (83.3)
Fatigue
Present 51 (100.0) 48 (96.0)
Bothersome (of those with fatigue ‘present’) 49 (96.1) 48 (100.0)
Number of symptoms frequency (%)
2 22 (43.1) 18 (36.0)
3 29 (56.9) 32 (64.0)
WHO score frequency (%)
Restricted in strenuous activity 21 (52.5) 25 (61.0)
Ambulatory/capable of all self-care 19 (47.5) 16 (39.0)
Patient treatment group frequency (%)
No further active cancer therapy 7 (13.7) 5 (10.0)
Post-curative treatment 18 (35.3) 19 (38.0)
Palliative cancer therapy follow-up 26 (51.0) 26 (52.0)
COPD frequency (%)
Yes 25 (50.0) 14 (28.0)
No 25 (50.0) 36 (72.0)
Prescribed opioids
Yes 18 (36.7) 16 (32.0)
Prescribed benzodiazepines
Yes 2 (4.0) 3 (6.0)
RDSI Respiratory Distress Symptom Intervention, COPD chronic obstructive pulmonary disease
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Table 2 Patient preference at
baseline for the different outcome
measures
Control RDSI
N Mean (SD) N Mean (SD) N Mean (SD)
Six NRS combined
How easy to complete 101 6.5 (2.9) 51 6.3 (3) 50 6.7 (2.9)
How relevant 101 6.8 (2.9) 51 7.2 (2.6) 50 6.5 (3.1)
Dyspnoea-12
How easy to complete 101 6.6 (2.9) 51 6.3 (3) 50 6.8 (2.8)
How relevant 101 7.1 (2.8) 51 7 (2.8) 50 7.1 (2.8)
Manchester Cough in Lung Cancer Scale
How easy to complete 91 7.3 (2.7) 47 7.2 (2.8) 44 7.4 (2.5)
How relevant 91 7.6 (2.4) 47 7.7 (2.3) 44 7.5 (2.5)
Fatigue (FACIT-F)
How easy to complete 100 7.3 (2.6) 51 6.9 (2.6) 49 7.7 (2.6)
How relevant 100 7.8 (2.4) 51 7.8 (2.3) 49 7.9 (2.5)
Hospital anxiety and depression scale
How easy to complete 99 7.5 (2.4) 51 7.3 (2.5) 48 7.7 (2.5)
How relevant 99 7.5 (2.6) 51 7.3 (2.8) 48 7.8 (2.2)
Lung Cancer Symptom Scale
How easy to complete 98 7.3 (2.6) 50 6.7 (3.1) 48 8.1 (1.6)
How relevant 98 7.6 (2.5) 50 7.3 (2.9) 48 7.8 (1.9)
EQ-5D
How easy to complete 101 7.8 (2.5) 51 7.4 (2.7) 50 8.2 (2.2)
How relevant 101 7.8 (2.7) 51 7.8 (2.5) 50 7.7 (2.8)
NRS numerical rating scale, EQ-5D Euro-Qual, RDSI Respiratory Distress Symptom Intervention
Table 3 Analysis of respiratory symptom cluster outcomes: mean change scores from baseline to week 4 and baseline to week 12
Mean (SD) difference (week 4–baseline) Mean (SD) difference (week 12–baseline)
Control RDSI Control RDSI
Breathlessness—NRS
Average breathlessness −0.38 (2.21) −0.06 (1.55) −0.75 (2.33) −0.17 (2.00)
Worst breathlessness −0.38 (2.55) −0.45 (2.06) −0.56 (2.7) −0.34 (2.59)
Relief breathlessness −0.55 (3.27) 0.41 (3.16) −0.38 (3.34) 0.68 (3.5)
Distress breathlessness 0.03 (2.26) −0.63 (1.9) −0.88 (2.9) −1.07 (2.07)
Ability to cope 0.81 (2.74) 0.5 (2.62) 0.5 (2.97) 1.03 (2.63)
Unpleasant 0.13 (2.97) −0.27 (2.23) −0.25 (3.09) −0.07 (2.39)
Dyspnoea−12 −2.13 (7.41) −2.98 (7.46) −1.52 (8.31) −3.04 (7.78)
Cough—MCLC −1.00 (6.33) −1.69 (5.91) −2.26 (8.84) −0.86 (7.02)
Fatigue—FACIT −2.44 (9.19) −1.45 (9.5) −1.28 (9.47) −1.64 10.01)
Lung Cancer Symptom Scale −17.83 (132.79) −27.68 (129.54) −21.90 (121.71) 7.48 (118.88)
HADS
Anxiety scale 0.06 (2.85) 0.31 (3.08) −0.06 (3.10) 0.81 (2.75)
Depression scale 0.58 (2.66) 0.64 (2.39) 1.22 (3.97) 0.70 (3.14)
EQ-5D Score 0.02 (0.29) 0.06 (0.23) −0.05 (0.33) 0.06 (0.28)
EQ-5D Health State Today (VAS) −3.30 (18.94) 0.40 (24.14) −4.50 (21.03) −2.20 (2.53)
NRS numerical rating scale,MCLCManchester Cough in Lung Cancer Scale, HADS Hospital Anxiety and Depression Scale, EQ-5D Euro-Qual, VAS
visual analogue scale, RDSI Respiratory Distress Symptom Intervention
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a MCLC MCID of 4.4. Based on these analyses, a MCLC
MCID estimate of 3 U was used in the sample size calculation.
To detect a difference of 3 U in MCLC, a sample size of 81
patients per arm at week 12 is required, and allowing for attri-
tion at week 12, then 102 per am should be recruited.
For fatigue, the FACIT-F was used which has a published
MCID of 3 to 4 U [36,38]. The FACIT-F had a mean differ-
ence between the two treatment groups of 4.8 U. Therefore, a
FACIT-F MCID of 4 U was used in the sample size calcula-
tion. To detect a difference of 4 U in FACIT-F, a sample size of
80 patients per arm at week 12 is required, and allowing for
attrition at week 12, then 100 per arm should be recruited.
Therefore, by recruiting to the higher number required (i.e.
122 patients per arm) will provide 80 % power that meaning-
ful differences could be detected in all three symptoms in the
cluster, with overall type I error rate of 5 %.
Adherence to and perceptions of usefulness
of the intervention components
Between 19 and 32 patients completed the daily and weekly
diaries at any time point. Participants reported high adherence
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Fig. 2 Mean scores (95%CI) from baseline to 4 and 12 weeks. RDSI Respiratory Distress Symptom Intervention, D12 Dyspnoea-12 questionnaire,
MCLCManchester Cough in Lung Cancer questionnaire, FACT-F Functional Assessment of Chronic Illness Therapy-Fatigue
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to the intervention. Breathing exercises were practiced daily
for the first 4 weeks between 87 and 100 %, and weekly prac-
tice for the remaining 8 weeks was between 96 and 100 %;
acupressure was practiced for the first 4 weeks between 84 and
100 %, and weekly practice for the remaining 8 weeks was
between 91 and 96%; cough easing techniques were practiced
daily for the first 4 weeks between 32 and 63 %, and weekly
practice for the remaining 8 weeks was between 36 and 54 %.
The lower use of cough easing techniques is likely to be related
to the fewer number of participants that were bothered by
cough in the intervention group (35/50).
The majority of participants reported that the breathing
techniques were useful at least a little bit over the 12 weeks;
there were only seven responses to not at all (five on day 1 and
one during weeks 8 and 12). For cough easing techniques,
therewere six responses to not at all, all during the first 4 weeks
post-intervention. Eighteen not at all responses were reported
for usefulness of acupuncture; 16 were within the first 4 weeks.
Discussion
The aim of this study was to assess the feasibility and accept-
ability of a clinical trial of a new non-pharmacological inter-
vention for the management of the Respiratory Distress
Symptom Cluster, consisting of breathlessness-cough-fatigue,
in patients with lung cancer. This study has demonstrated that
it is feasible to conduct a larger trial that will recruit a suffi-
cient number of patients to determine whether or not the in-
tervention, RDSI, results in improved patient outcomes and is
cost-effective, compared to the control group. Participants re-
ported a high level of adherence to the different RDSI tech-
niques, and the majority of participants reported that each
component was useful over the 12-week study period; both
are important indicators of acceptability.
Screening identified that a proportion of patients were not
eligible to participate due to current or recent treatment with
chemotherapy or radiotherapy (21 %). Radiotherapy and che-
motherapy can improve the symptoms of breathlessness and
cough, but not fatigue [5], and hence may dilute the effect of
the intervention or lead to unclear results. In addition, our
previous work on intervention preferences demonstrated that
many patients are reluctant to participate in a study which
requires engagement of the sort needed to learn non-
pharmacological techniques whilst having such treatments
[17–19]. Therefore, we will retain these exclusion criteria in
the main trial but will decrease the post-chemotherapy time
from 4 weeks to 2 weeks and keep post radiotherapy at
4 weeks. The follow-on trial will have a built-in mechanism
for re-contacting patients following the exclusion time period.
Screening for potential participants in this multisite feasi-
bility study was challenging. Different sites often approached
this aspect differently, and it was difficult to obtain accurate
figures for non-participation in patients who met the inclusion
Table 4 Analysis of respiratory symptom cluster outcomes: GEE differences between groups, with 95%CI
Mean (SD) group difference at week 4 Mean (SD) group difference at week 12
Control-RDSI 95%CI p value Control-RDSI 95%CI p value
Breathlessness—NRS
Average breathlessness 0.64 (0.50) −0.34,1.61 0.2 0.65 (0.58) −0.49,1.80 0.26
Worst breathlessness 0.45 (0.55) −0.63,1.53 0.42 0.41 (0.65) −0.86,1.67 0.53
Relief breathlessness −0.58 (0.71) −1.97,0.81 0.42 −0.30 (0.66) −1.60,1.00 0.65
Distress breathlessness 1.46 (0.63) 0.23,2.69 0.02 0.75 (0.70) −0.63,2.13 0.29
Ability to cope −1.02 (0.63) −2.24,0.21 0.1 −1.01 (0.62) −2.22,0.21 0.11
Unpleasant 0.71 (0.63) −0.52,1.94 0.26 0.52 (0.75) 0.94,1.99 0.49
Dyspnoea-12
Total 4.32 (2.22) −0.03,8.67 0.05 5.19 (2.33) 0.62,9.75 0.026
Cough—MCLC 3.38 (1.87) −0.29,7.05 0.07 2.50 (2.41) 2.22,7.23 0.3
Fatigue—FACIT 2.84 (2.70) −2.45,8.13 0.3 4.98 (2.89) −0.68,10.63 0.09
Lung Cancer Symptom Scale 8.83 (4.29) 0.42,17.24 0.04 6.12 (4.40) −2.50,14.75 0.16
HADS
Anxiety scale 1.33 (1.08) −0.80,3.46 0.22 0.25 (0.97) −1.66,2.15 0.8
Depression scale 0.99 (1.10) −1.16,3.13 0.37 0.59 (1.19) −1.75,2.93 0.62
EQ-5D-3L Score −0.75 (0.07) −0.20,0.05 0.25 −0.17 (0.65) −0.30, −0.04 0.009
EQ-5D-3L Health State Today (VAS) −10.21 (5.47) −20.93,0.51 0.05 −9.88 (5.54) −20.75,0.99 0.08
NRS numerical rating scale,MCLCManchester Cough in Lung Cancer Scale, HADS Hospital Anxiety and Depression Scale, EQ-5D Euro-Qual, VAS
visual analogue scale, RDSI Respiratory Distress Symptom Intervention
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criteria on initial screening of medical notes. Across the 11
recruitment sites, 128 patients fell into this category mostly
due to the attending clinician not informing the patient about
the study for reasons such as medical issues or further inves-
tigations required, personal/family issues, time constraints in a
busy clinic and forgetting to mention the study during the
consultation.
Eligible patients were required to report the presence of at
least two of the three symptoms, in any combination, and per-
ceive them to be bothersome. The combination of symptoms
varies between and within patients and overtime [1]; however,
we only collected this information as part of eligibility criteria.
Feasibility data showed that, at study entry, breathlessness and
fatigue were present and bothersome for more than 97 % of
participants, and cough was present for 80 % and bothersome
for 80 % of those patients (66 % of the total sample). It is
possible that the approach used for screening questions result-
ed in fewer patients reporting bothersome cough, and this
needs to be amended in a future trial. Nonetheless, these fig-
ures are representative of the lung cancer population for symp-
tom prevalence [1–5]. Thirty percent of participants were post-
curative treatment, and we expect that this number can increase
through recruitment strategies targeting early diagnosis and
survivors post-radical treatment. Therefore, a 20 % attrition
rate was used to determine sample size for the follow-on study
and is comparable with similar studies in the past [10].
The method used for symptom screening consisted of two
questions: ‘Do you have breathlessness’; if ‘yes’, ‘Are you
bothered by your breathlessness?’, and repeated for each
symptom. This resulted in 25% of those screened not meeting
inclusion criteria. Following the feasibility study, we consulted
with a patient group not involved in the trial, who felt that
asking whether or not a symptom was present was too sim-
plistic and that the term bothered was suggestive of the patient
‘complaining’. For the follow-on trial, we will adopt the single
screening question suggested by the group: ‘Are you affected
in your day-to-day life by breathlessness?’ and repeated for
each symptom. Patients who at first approach report only one
or no symptoms will be reassessed for their study eligibility at
monthly intervals or until consent is withdrawn.
Despite the number of questionnaires that required comple-
tion, there was less than 5 % missing data. The research team
were conscious of the potential for responder burden during
the trial. Training was provided to the research assistants and
other trial recruiters to ensure that potential participants were
fully-informed about the amount of required questionnaire
completion. Follow-up packs were presented in colour-
coded sections and presented in organised folders to help mo-
tivate people to complete them. Ethical approval was also
sought to provide for one follow-up reminder telephone call.
Few patients withdrew due to the amount of required paper-
work. These techniques appeared to be successful and will be
used in the subsequent trial.
This study was unique in that the intervention included a
‘package’ of different techniques that patients could choose
from depending on their symptom experience at any particular
time. Patients could use one or all of the techniques through-
out the duration of the study. This is a similar approach suc-
cessfully used in the management of breathlessness with com-
plex interventions, whereby a number of different techniques
are taught to patients [9,10,20]; however, we included inter-
ventions that also targeted cough and fatigue. In view of the
evidence for structured activity for the management of cancer-
related fatigue [39,40], the follow-on trial will include an in-
dividually tailored exercise plan as a core component of
RDSI. This was also supported by our patient representative
group. Likewise, Chan and colleagues [41] evaluated a non-
pharmacological intervention for the management of anxiety-
breathlessness-fatigue in lung cancer; the intervention
consisted of a combination of education and relaxation and
was reported to improve patients’ symptom experience.
Since the intervention was targeted at alleviating two or
three distressing symptoms, part of our aim was to determine
the most appropriate outcome measure for each symptom and
to determine the MCID of the assessments used, allowing a
sample size calculation for a powered study. The feasibility
study included NRS scales in addition to the Dyspnoea-12,
and we found that the Dyspnoea-12 provided the largest effect
size, compared to any of the single item NRS scores. It also
provides an assessment of total breathlessness severity that in-
corporates its physical discomfort and emotional conse-
quences; this negates the need to use multiple NRS scores [21].
One challenge of evaluating the effectiveness of interven-
tions aimed at ameliorating a cluster of symptoms is identifi-
cation of a suitable outcome measure. The complexity of the
Respiratory Distress Symptom cluster is an issue, whereby the
combination of symptom occurrence differs between and
within patients over time [1]. We applied a symptom-
specific measure for each symptom in the cluster which ne-
cessitated a sample size calculation to be performed for each
symptom. That analysis determined that a sample size of 122
patients per arm, based on the Dyspnoea-12 for breathless-
ness, would enable a meaningful difference to be captured in
the outcome assessment used for cough and fatigue.
Therefore, the follow-on study will have three primary out-
comes: breathlessness, cough and fatigue. Consideration was
also given to providing a composite score for the symptom
cluster, as done in a past study [41]. However, this proved
difficult since patients experienced symptoms in different
combinations, with some experiencing all three symptoms
and some experiencing only two. In this study, symptom prev-
alence was only collected as baseline.
This study was able to demonstrate the sensitivity of the
EQ-5D-3 L to detect relevant changes in HRQoL. Recent
developments by the EuroQol group have made available an
updated version of the instrument to include five levels for
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each domain resulting in the EQ-5D-5 L, thereby providing a
potentially more sensitive measure for use in the follow-on
trial [42].
Due to the nature of the intervention and trial design,
blinding was not possible for the therapist delivering the in-
tervention. Researchers’ collecting outcome data were not
blind to allocation which possess an additional limitation.
Researcher blinding to group allocation will be implemented
for the collection of outcome measures in the follow-on study.
The study was underpowered, focusing primarily on feasibil-
ity issues; hence, interpretation of comparative data between
groups should be with caution. Data on oxygen use or steroids
was not collected, and this may influence some of the results.
Also, the groups differed in relation to COPD status and total
symptom burden, two variables that need to be considered
more carefully in a future trial and balanced accordingly.
Conclusion
The study has provided evidence of the feasibility and accept-
ability of a new intervention in the lung cancer population and
warrants a fully powered trial before we reach any conclu-
sions. Results were positive, with activity for RDSI at 4 and
12 weeks, a trend towards better results in the intervention
group. Intervention acceptability was confirmed, and of par-
ticular note, no patients withdrew from the intervention group
after week 4 which suggests that once participants became
familiar with the intervention, they remained in the study. In
this population of patients in often advanced stages of their
illness and with complex symptomatology but limited symp-
tom management options, it is imperative to test and, if found
effective, subsequently to introduce new interventions that can
improve the patients’ symptom experience.
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